Brief introduction of Beijing Wan Tai biopharmaceutical Co., Ltd.

The company was established in 199 1. After 20 years of development and accumulation, it has developed from a small-scale laboratory at the beginning of its establishment into a modern diagnostic reagent production base with an area of 35,000 square meters and a building area of 20,000 square meters. With more than 450 employees, the company has become the largest AIDS diagnostic reagent production base in the Asia-Pacific region, the largest immunodiagnostic reagent in China and the national bio-high technology industrialization demonstration project base.

The company's product line is gradually increasing, except for producing HIV, HBV, HCV, HEV, syphilis (TP, TRUST), rotavirus (RV), T-lymphocytic leukemia virus (HTLV) and enterovirus 7 1 (EV7 1).

With the continuous enrichment of product line and the gradual expansion of sales network, it has become the largest supplier of blood transfusion safety diagnosis products in China. Sales continued to grow rapidly, reaching 280 million yuan in 20 10, with a compound annual growth rate of over 25%.

As one of the earliest units engaged in the research and development of HIV diagnostic reagents in China, the series of HIV diagnostic reagents developed and produced by the company have the advantages of high sensitivity, good specificity and stable quality, and the market share has been the first in China for 8 consecutive years (2003-20 10). With strong scientific research strength and rich market experience, the company is constantly committed to short-,medium-and long-term product innovation, and constantly introduces the third generation, fourth generation and colloidal gold HIV detection reagents, and will launch saliva, urine and other rapid diagnosis products and HIV confirmation reagents in the near future to maintain the leading position in the HIV series products industry.